Transmitted Antiretroviral Drug Resistance in Newly HIV-Infected and Untreated Patients in Ségou and Bamako,Mali

Abstract

The WHO recommends regular surveillance for transmitted antiretroviral drug-resistant viruses in HIV antiretroviral treatment (ART)-naive patients in resource-limited settings. This study aimed to assess the prevalence of mutations associated with resistance in ART-naive patients newly diagnosed with HIV in Bamako and Ségou in Mali. HIV-positive patients who never received ART were recruited in Bamako and Ségou, Mali. The reverse transcriptase (RT) and protease (PR) genes of these patients were sequenced by the “ViroSeq” method. Analysis and interpretation of the resistance were made according to the WHO 2009 list of drug resistance mutations. In all, 51/54 (94.4%) sample patients were sequenced. The median age (IQR) of our patients was 24 (22–27) years and the median CD4 count was 380 (340–456) cells/mm³. The predominant subtype was recombinant HIV-1 CRF02_AG (66.7%) followed by CRF06_cpx (12%) and CRF09_cpx (4%). Four patients had mutations associated with resistance, giving an overall prevalence of resistance estimated at 7.9%. There were two (4%) patients with nucleoside reverse transcriptase inhibitor (NRTI) mutations (one M184V and one T215Y), two (4%) with non-NRTI mutations (two K103N), and one (2%) with a protease inhibitor mutation (one I54V). The prevalence of primary resistance in newly infected patients in Mali is moderate (7.9%). This indicates that the standard NNRTI-based first-line regimen used in Mali is suboptimal for some patients. This study should be done regularly to inform clinical practice.

Get full access to this article

View all access options for this article.

References

Samake

, Traore

, Ba

et al. Quatrieme Enquête Démographique et de Santé du Mali. EDSMIV, 2006CPS/MS410.

Maiga

, Marcelin

, Fofana

et al. Virological failure to second-line antiretroviral treatment, profile of resistance mutations among patients infected with HIV-1 in Bamako. 18th IAS Conference in Vienna, 2010Abstract TUPE0127.

Tebit

, Sangare

, Tiba

et al. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naive patients in Burkina Faso. J Med Virol, 2009; 81,10:1691–1701.

Ayouba

, Lien

, Nouhin

et al. Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Cote d'Ivoire, Senegal, Thailand, and Vietnam: The ANRS 12134 study. AIDS Res Hum Retroviruses, 2009; 25,11:1193–1196.

Toni

, Masquelier

, Minga

et al. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Cote d'Ivoire: A 4-year survey, 2002–2006. AIDS Res Hum Retroviruses, 2007; 23,9:1155–1160.

Derache

, Maiga

, Traore

et al. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother, 2008; 62,3:456–463.

Derache

, Traore

, Koita

et al. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antivir Ther, 2007; 12,1:123–129.

Haidara

, Chamberland

, Sylla

et al. High level of primary drug resistance in Mali. HIV Med, 2010; 11,6:404–411.

Abreu

, Brindeiro

, Martins

et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 isolates circulating in pregnant women from Mozambique. Arch Virol, 2008; 153,11:2013–2017.

10.

Eshleman

, Laeyendecker

, Parkin

et al. Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. AIDS, 2009; 23,7:845–852.

11.

Galluzzo

, Germinario

, Bassani

et al. Antiretroviral resistance mutations in untreated pregnant women with HIV infection in Uganda and Rwanda. AIDS Res Hum Retroviruses, 2007; 23,11:1449–1451.

12.

Hamers

, Siwale

, Wallis

et al. HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr, 2011; 55,1:95–101.

13.

Charpentier

, Bellecave

, Cisse

et al. High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger. Antivir Ther, 2011; 16,3:429–433.

14.

Bennett

, Camacho

, Otelea

et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One, 2009; 4,3:e4724.

15.

Johnson

, Li

, Wei

et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med, 2008; 5,7:e158.

16.

Paredes

, Lalama

, Ribaudo

et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis, 2010; 201,5:662–671.